Desloratadine + Zyrtec® (cetirizine)
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Allergies
Conditions
Allergies
Trial Timeline
Aug 1, 2005 → Oct 1, 2005
NCT ID
NCT00780403About Desloratadine + Zyrtec® (cetirizine)
Desloratadine + Zyrtec® (cetirizine) is a approved stage product being developed by Organon for Allergies. The current trial status is completed. This product is registered under clinical trial identifier NCT00780403. Target conditions include Allergies.
What happened to similar drugs?
1 of 1 similar drugs in Allergies were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00779116 | Approved | Completed |
| NCT00780403 | Approved | Completed |
Competing Products
5 competing products in Allergies
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0524 | Merck | Phase 2 | 35 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 27 |
| Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) | Sandoz Group | Phase 1 | 26 |
| Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA) + Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA) | Sandoz Group | Phase 1 | 26 |
| Desloratadine + Zyrtec® (cetirizine) | Organon | Approved | 37 |